Delving into the Latest Updates on Travoprost/Timolol Maleate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

DuoTrav APS, DuoTrav BAK, DuoTrav PQ

+ [11]

Target

PTGFR x β-adrenoceptors

Mechanism

PTGFR agonists(Prostanoid FP receptor agonists), β-adrenoceptors antagonists(Beta adrenergic receptors antagonists)

Therapeutic Areas

Eye Diseases

Active Indication

GlaucomaGlaucoma, Open-AngleOcular Hypertension

Inactive Indication-

Originator Organization

Alcon AG

Active Organization

Novartis Europharm Ltd.

Novartis Pharmaceuticals Corp.

Inactive Organization

Alcon Research Ltd.

Drug Highest PhaseApproved

First Approval Date

EU (23 Apr 2006),

Glaucoma, Open-AngleOcular Hypertension

RegulationPriority Review (CN)

Login to view timeline

Structure

Molecular FormulaC39H59F3N4O9S

InChIKeyKJNUGXGYVXURJB-DDANCUEQSA-N

CAS Registry874755-80-3

The purpose of this study is to assess efficacy and tolerability of changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-free) from prior Xalacom® or Ganfort® fixed combination pharmacotherapy in patients with open-angle glaucoma or ocular hypertension with uncontrolled intraocular pressure (IOP).

Start Date01 Jun 2012

Sponsor / Collaborator

Alcon Research Ltd.

100 Clinical Results associated with Travoprost/Timolol Maleate

Login to view more data

100 Translational Medicine associated with Travoprost/Timolol Maleate

Login to view more data

100 Patents (Medical) associated with Travoprost/Timolol Maleate

Login to view more data

69

Literatures (Medical) associated with Travoprost/Timolol Maleate

01 Aug 2024·Vaccine

Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus

Article

Author: Wang, Yi ; Gu, Jiang ; Wu, Meilin ; Wan, Jiqing ; Cheng, Xin ; Luo, Ping ; Chen, Yuan ; He, Qinggang ; Li, Xiaoyan ; Li, Yuhang ; Zhang, Yi

The conventional inactivated tetanus toxin plays an instrumental role in preventing tetanus. Nevertheless, the challenges associated with its production process, the potential for adverse reactions, and reduced effectiveness in vulnerable populations such as neonates and the elderly rise the need for a novel tetanus toxin vaccine. Recombinant subunit vaccine offer a viable solution, and the tetanus toxin fragment C (TTFC) is emerging as a promising candidate. In this study, through spontaneous isopeptide bond formation we conjugated the recombinant TTFC to self-assembled mi3 nanoparticle, which derived from an optimized KDPG aldolase, and generated the TTFC-mi3 protein nanoparticle vaccine. We found that TTFC-mi3 is stable, uniform spherical nanoparticles. Comparing with the free TTFC alone, TTFC-mi3 enhances the uptake and subsequent activation of dendric cells (DCs). In addition, a single dose of adjuvant-free TTFC-mi3 elicited a more rapid and potent protective immunity in mice. Moreover, TTFC-mi3 is of favorable safety in vitro and in vivo. Our findings indicate that TTFC-mi3 is a rapid-response, non-aluminum-adjuvanted vaccine against tetanus.

05 Sep 2022·Journal of EpidemiologyQ3 · MEDICINE

Association of the Time to First Cigarette and the Prevalence of Chronic Respiratory Diseases in Chinese Elderly Population

Q3 · MEDICINE

ArticleOA

Author: Wang, Chao ; Lou, Yiling ; Cao, Shiyi ; Jiang, Heng ; Lu, Zuxun ; Gan, Yong ; Guo, Yingying ; Tian, Qingfeng ; Zhu, Yi

BACKGROUNDIncreasing number of studies have suggested the time to first cigarette after waking (TTFC) have significant positive effect on respiratory diseases. However, few of them focused on the Chinese population. This study aims to estimate the impact of TTFC on the prevalence of chronic respiratory diseases (CRD) in Chinese elderly and explore the association in different sub-populations.METHODSCross-sectional data of demographic characteristics, living environment, smoking-related variables, and CRD were drawn from the Chinese Longitudinal Healthy Longevity Survey in 2018. Multivariate stepwise logistic regression analyses were conducted to examine the association of the TTFC with the prevalence of CRD.RESULTSThis study includes 13,208 subjects aged 52 years and older, with a mean age of 85.3 years. Of them, 3,779 participants were ex- or current smokers (44.9% had the TTFC ≤30 minutes, 55.1% >30 minutes) and 1,492 had suffered from CRD. Compared with non-smokers, participants with TTFC ≤30 minutes seemed to have higher prevalence of CRD (OR 1.97; 95% CI, 1.65-2.35) than those with TTFC >30 minutes (OR 1.70; 95% CI, 1.44-2.00), although the difference was statistically insignificant (P_interaction = 0.12). Compared with TTFC >30 minutes, TTFC ≤30 minutes could drive a higher prevalence of CRD among female participants, those aged 90 years and older, urban residents, and ex-smokers (P_interaction < 0.05).CONCLUSIONShorter TTFC relates to higher prevalences of CRD in Chinese older females, those aged 90 years and older, urban residents, and ex-smokers. Delaying TTFC might partially reduce its detrimental impact on respiratory disease in these specific subpopulations.

01 Dec 2020·Microbial Cell FactoriesQ2 · ENGINEERING & TECHNOLOGY

A probiotic treatment increases the immune response induced by the nasal delivery of spore-adsorbed TTFC

Q2 · ENGINEERING & TECHNOLOGY

ArticleOA

Author: Mazzoli, Arianna ; Leite, Fabio ; Ricca, Ezio ; Isticato, Rachele ; Baccigalupi, Loredana ; Santos, Francisco Denis S ; Maia, Ana Raquel ; Saggese, Anella ; Iossa, Susanna

AbstractBackgroundSpore-forming bacteria of the Bacillus genus are widely used probiotics known to exert their beneficial effects also through the stimulation of the host immune response. The oral delivery of B. toyonensis spores has been shown to improve the immune response to a parenterally administered viral antigen in mice, suggesting that probiotics may increase the efficiency of systemic vaccines. We used the C fragment of the tetanus toxin (TTFC) as a model antigen to evaluate whether a treatment with B. toyonensis spores affected the immune response to a mucosal antigen.ResultsPurified TTFC was given to mice by the nasal route either as a free protein or adsorbed to B. subtilis spores, a mucosal vaccine delivery system proved effective with several antigens, including TTFC. Spore adsorption was extremely efficient and TTFC was shown to be exposed on the spore surface. Spore-adsorbed TTFC was more efficient than the free antigen in inducing an immune response and the probiotic treatment improved the response, increasing the production of TTFC-specific secretory immunoglobin A (sIgA) and causing a faster production of serum IgG. The analysis of the induced cytokines indicated that also the cellular immune response was increased by the probiotic treatment. A 16S RNA-based analysis of the gut microbial composition did not show dramatic differences due to the probiotic treatment. However, the abundance of members of the Ruminiclostridium 6 genus was found to correlate with the increased immune response of animals immunized with the spore-adsorbed antigen and treated with the probiotic.ConclusionOur results indicate that B. toyonensis spores significantly contribute to the humoral and cellular responses elicited by a mucosal immunization with spore-adsorbed TTFC, pointing to the probiotic treatment as an alternative to the use of adjuvants for mucosal vaccinations.

2

News (Medical) associated with Travoprost/Timolol Maleate

06 Sep 2022

·www.globenewswire.com

Eyenovia to Participate in Multiple Medical Meetings in September

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that the company will be participating in multiple medical meetings in September. Details of the presentations are as follows: Meeting: Ophthalmology Futures European Forum 2022Title: The Optejet – Advancing Drug Delivery and Improving Patient ExperiencePresenter: Beth Scott, OD, VP, Regulatory and Medical AffairsDate: Thursday, September 15, 2022Location: Principe di Savoia, Milan, Italy Meeting: The T.H.E. Summit by Treehouse EyesTitle: Drug/Device Technology to Improve Pediatric Progressive Myopia TreatmentPresenter: Michael Rowe, Chief Executive OfficerDate: September 15, 2022Location: Caesars, Las Vegas, NV Meeting: 40th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) 2022Title: In Vitro Cell Toxicity Comparing Microdose vs Drop Delivery of Latanoprost with BAK in Human Conjunctival CellsPresenter: Pedram Hamrah, MD, FACS, Department of Ophthalmology, Tufts Medical CenterDate: September 16-20, 2022Format: ePoster presentation, accessible for the duration of the conferenceLocation: Milano Convention Centre, Milan, Italy Meeting: Eyecelerator at AAO 2022Title: The Optejet® | The First and Only Human-Centric Ophthalmic Topical Medication DevicePresenter: Michael Rowe, Chief Executive OfficerDate: Thursday, September 29, 2022Location: McCormick Place, Chicago, Il About Eyenovia, Inc.Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAPTM) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit Eyenovia.com. The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations. Forward-Looking StatementsExcept for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements. Eyenovia Contact:Eyenovia, Inc.John GandolfoChief Financial Officerjgandolfo@eyenovia.com Eyenovia Investor Contact:Eric RibnerLifeSci Advisors, LLCeric@lifesciadvisors.com(646) 751-4363 Eyenovia Media Contact:Eyenovia, Inc.Norbert LoweVice President, Commercial Operationsnlowe@eyenovia.com

06 Sep 2022

·www.biospace.com

Eyenovia to Participate in Multiple Medical Meetings in September 2022

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that the company will be participating in multiple medical meetings in September. Details of the presentations are as follows: Meeting: Ophthalmology Futures European Forum 2022 Title: The Optejet – Advancing Drug Delivery and Improving Patient Experience Presenter: Beth Scott, OD, VP, Regulatory and Medical Affairs Date: Thursday, September 15, 2022 Location: Principe di Savoia, Milan, Italy Meeting: The T.H.E. Summit by Treehouse Eyes Title: Drug/Device Technology to Improve Pediatric Progressive Myopia Treatment Presenter: Michael Rowe, Chief Executive Officer Date: September 15, 2022 Location: Caesars, Las Vegas, NV Meeting: 40th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) 2022 Title: In Vitro Cell Toxicity Comparing Microdose vs Drop Delivery of Latanoprost with BAK in Human Conjunctival Cells Presenter: Pedram Hamrah, MD, FACS, Department of Ophthalmology, Tufts Medical Center Date: September 16-20, 2022 Format: ePoster presentation, accessible for the duration of the conference Location: Milano Convention Centre, Milan, Italy Meeting: Eyecelerator at AAO 2022 Title: The Optejet® | The First and Only Human-Centric Ophthalmic Topical Medication Device Presenter: Michael Rowe, Chief Executive Officer Date: Thursday, September 29, 2022 Location: McCormick Place, Chicago, Il About Eyenovia, Inc. Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAPTM) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit Eyenovia.com. The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations. Forward-Looking Statements Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements. Eyenovia Contact: Eyenovia, Inc. John Gandolfo Chief Financial Officer jgandolfo@eyenovia.com Eyenovia Investor Contact: Eric Ribner LifeSci Advisors, LLC eric@lifesciadvisors.com (646) 751-4363 Eyenovia Media Contact: Eyenovia, Inc. Norbert Lowe Vice President, Commercial Operations nlowe@eyenovia.com

100 Deals associated with Travoprost/Timolol Maleate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	S01ED51	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	JP	Novartis Pharmaceuticals Corp.	16 Apr 2010
Glaucoma, Open-Angle	EU	Novartis Europharm Ltd.	23 Apr 2006
Glaucoma, Open-Angle	LI	Novartis Europharm Ltd.	23 Apr 2006
Glaucoma, Open-Angle	IS	Novartis Europharm Ltd.	23 Apr 2006
Glaucoma, Open-Angle	NO	Novartis Europharm Ltd.	23 Apr 2006
Ocular Hypertension	LI	Novartis Europharm Ltd.	23 Apr 2006
Ocular Hypertension	IS	Novartis Europharm Ltd.	23 Apr 2006
Ocular Hypertension	NO	Novartis Europharm Ltd.	23 Apr 2006
Ocular Hypertension	EU	Novartis Europharm Ltd.	23 Apr 2006

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glaucoma, Open-Angle	Phase 2	US	Alcon Research Ltd.	01 Mar 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ARVO2019	Not Applicable	Glaucoma	152	Xalacom	(sktlnbvrrz) = yizvuylmhs ttbjwgykor (iqlfvomkmq )	-	01 Jul 2019
				Duo Trav	(sktlnbvrrz) = iskdoptqlo ttbjwgykor (iqlfvomkmq )
NCT02730871 (CTgov)	Phase 4	Glaucoma, Open-Angle	173	Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension+Travoprost 0.004%/timolol 0.5% solution (Simbrinza + Duotrav)	ktgvhwdovt(chbatwkzjt) = lybzqsbmsy udbuffstbx (ldgtktmlkh, hmztpqhfyv - xfmouajutc) View more	-	17 May 2019
				Brinzolamide/brimonidine vehicle+Travoprost 0.004%/timolol 0.5% solution (Vehicle + Duotrav)	ktgvhwdovt(chbatwkzjt) = eeecavrmdw udbuffstbx (ldgtktmlkh, zlwtnprgqc - ecradxtgxe) View more
NCT02003391 (CTgov)	Phase 4	Glaucoma, Open-Angle	157	Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution (DuoTrav)	cwysiwsguv(ffxbtsiyfi) = twwzqqncpw mjtpoqwimx (iydkpbnhcr, xbixkulgpx - uqehlgtarm) View more	-	08 Aug 2016
				Beta-blocker monotherapy+Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution (Beta-blocker)	cwysiwsguv(ffxbtsiyfi) = teshyitcjo mjtpoqwimx (iydkpbnhcr, kpiaanedzv - yzcvyauyek) View more
NCT01547598 (CTgov)	Phase 4	Glaucoma, Open-Angle	135	Bimatoprost ophthalmic solution 0.01%+travoprost ophthalmic solution 0.004% (LUMIGAN® RC)	wosfsrgpci(svgahnynlq) = uhxwfjneio natmfgjpso (owvlusxcft, wlkbkcjpyk - bubfenfdga) View more	-	15 Aug 2014
				travoprost ophthalmic solution 0.004%+travoprost 0.004% / timolol 0.5% combination ophthalmic solution (DuoTrav®)	wosfsrgpci(svgahnynlq) = geauqzdlno natmfgjpso (owvlusxcft, ecyucptimw - ksywkjjrxb) View more
NCT01327599 (CTgov)	Phase 4	Glaucoma-Related Pigment Dispersion Syndrome	60	Travoprost 0.004%+Timolol 0.5% ophthalmic solution	ytmkfqfvsv(ypayecnref) = whspcarksv vgcduxtbcf (dojkddxyyh, kddbupsuoj - xnjrflrmnp) View more	-	10 Jan 2014
NCT01336569 (CTgov)	Phase 4	Glaucoma, Open-Angle	50	Travoprost 0.004%/timolol maleate 0.5% fixed combination	lthlcytuqe(oytvwlmowm) = fwlwudqpub tmnebimexz (xwziapcwhz, pndwdcutzu - vlrmrfpygo) View more	-	08 Jul 2013
NCT00508469 (CTgov)	Phase 4	Glaucoma, Open-Angle	102	Travalert Dosing Aid+Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) (Travalert With Travoprost/Timolol Fixed Combination)	xlqgrnjnqp(dyrjbyknzh) = btkbzvyeic xwbyalvbqg (tsavytetqi, nbfpajlvec - whyizmgvui) View more	-	12 Jul 2012
				Travalert Dosing Aid+Timolol 0.05% eye drops+Travoprost 0.004% eye drops (Travalert With Travoprost and Timolol)	xlqgrnjnqp(dyrjbyknzh) = njgcqwcwcx xwbyalvbqg (tsavytetqi, nnqwcblpnf - gctjovtzpu) View more
ARVO2010	Not Applicable	Glaucoma	45	Travoprost/timolol	gtnzxtxrmu(wmnorsiddh) = ykcuyfzdew auguhoacbq (eiultfdmzj ) View more	-	01 Apr 2010
				Glaucoma patients treated with bimatoprost/timolol	gtnzxtxrmu(wmnorsiddh) = rhlfxvtztx auguhoacbq (eiultfdmzj ) View more
NCT00444184 (ARVO2008)	Phase 4	Glaucoma, Open-Angle	34	Travoprost/Timolol Fixed Combination	(enpjvvjfsl) = lipdmxoklv efzwotyyhj (bosldjlwws )	Positive	01 May 2008
				Travoprost	(enpjvvjfsl) = ejxcxwpvca efzwotyyhj (bosldjlwws )
ARVO2006	Not Applicable	-	-	Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution	(gmbfoiudtr) = stgzmruiji fzhmdglgpu (xhtnlsqoet )	-	01 May 2006
				Xalatan and Timolol 0.5%	(gmbfoiudtr) = emjdigydbo fzhmdglgpu (xhtnlsqoet )